Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors
Absolute iron deficiency is treated by correcting the causative lesion and then, traditionally, administering sufficient amounts of ferrous salt to return the haemoglobin level to normal and replenish body stores. The bioavailability of ferric compounds has been questioned and accordingly their therapeutic role remains controversial. A special problem is posed by regular blood donation, where the frequency of phlebotomy is limited by the haemoglobin level, which, in turn, requires maintenance of an adequate supply of iron from dietary sources. Since this latter situation may not always occur, it would be of practical benefit to have a form of supplementation that is effective and can be taken without side effects. These issues were prospectively examined in a consecutive series of otherwise healthy blood donors who developed absolute iron deficiency anaemia and were then randomly allocated to receive 60 mg of this metal as ferrous sulphate twice a day (Group 1: n = 51), 100 mg as chewable ferric polymaltose daily (Group 2: n = 53), or the latter product twice a day (Group 3: n = 55). Serial studies showed that 80% of patients in Groups 1 and 3 had reached normal haemoglobin levels by 12 weeks, but this figure was only 50% in Gr...Continue Reading
Biochemical skeletal muscle and hematological profiles of moderate and severely iron deficient and anemic adult rats
Influence of blood donation on iron stores assessed by serum ferritin and haemoglobin in a population survey of 1433 Danish males
Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors
Volunteer blood donors who fail the copper sulfate screening test. What does failure mean, and what should be done?
Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors
Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate
Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview
Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study
Efficacy, Tolerability, and Acceptability of Iron Hydroxide Polymaltose Complex versus Ferrous Sulfate: A Randomized Trial in Pediatric Patients with Iron Deficiency Anemia
Intestinal helminth infections, anaemia and labour productivity of female tea pluckers in Bangladesh
The effect of weekly iron supplementation on anaemia and on iron deficiency among female tea pluckers in Bangladesh
Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors
Erythrocytes: Better Tolerance of Iron Polymaltose Complex Compared with Ferrous Sulphate in the Treatment of Anaemia
Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.